These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10025889)

  • 1. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
    Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
    Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
    Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
    Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy.
    Osman Y; Takahashi M; Zheng Z; Toba K; Liu A; Furukawa T; Narita M; Aizawa Y; Koike T; Shibata A
    J Exp Clin Cancer Res; 1999 Dec; 18(4):485-92. PubMed ID: 10746975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
    Norbury LC; Clark RE; Christmas SE
    Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
    Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
    Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
    Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
    Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR-ABL-specific CD4
    Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
    Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-alpha.
    Wang C; Al-Omar HM; Radvanyi L; Banerjee A; Bouman D; Squire J; Messner HA
    Exp Hematol; 1999 Jul; 27(7):1176-84. PubMed ID: 10390193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.
    Mannering SI; McKenzie JL; Fearnley DB; Hart DN
    Blood; 1997 Jul; 90(1):290-7. PubMed ID: 9207464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
    He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
    Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
    Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
    Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
    Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
    Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
    Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells.
    Dietz AB; Bulur PA; Erickson MR; Wettstein PJ; Litzow MR; Wyatt WA; Dewald GW; Tefferi A; Pankratz VS; Vuk-Pavlović S
    J Hematother Stem Cell Res; 2000 Feb; 9(1):95-101. PubMed ID: 10738977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response.
    Eibl B; Ebner S; Duba C; Böck G; Romani N; Erdel M; Gächter A; Niederwieser D; Schuler G
    Genes Chromosomes Cancer; 1997 Nov; 20(3):215-23. PubMed ID: 9365828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
    Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
    Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
    Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-derived b2a2-specific T cells for immunotherapy of patients with chronic myeloid leukemia.
    Crough T; Nieda M; Morton J; Bashford J; Durrant S; Nicol AJ
    J Immunother; 2002; 25(6):469-75. PubMed ID: 12439344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
    Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
    Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro.
    Syme R; Bryan T; Duggan P; Bajwa R; Stewart D; Glück S
    Stem Cells Dev; 2004 Apr; 13(2):211-21. PubMed ID: 15186738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.